{"id":12578,"date":"2023-09-22T14:44:41","date_gmt":"2023-09-22T12:44:41","guid":{"rendered":"https:\/\/iph-multisite.berta-bewegt.ch\/?p=12578"},"modified":"2026-03-03T11:18:13","modified_gmt":"2026-03-03T10:18:13","slug":"communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/","title":{"rendered":"Communiqu\u00e9 de presse : R\u00e9vision de l\u2019OAMal : la tactique de r\u00e9duction des co\u00fbts menace la prise en charge dans les cas m\u00e9dicaux exceptionnels"},"content":{"rendered":"\n<p class=\"is-style-paragraph-lead-text\"><strong>Par la r\u00e9vision de l\u2019Ordonnance sur l\u2019assurance-maladie, le Conseil f\u00e9d\u00e9ral fait des \u00e9conomies suppl\u00e9mentaires de plus de 250&nbsp;millions de francs dans le domaine des m\u00e9dicaments. L\u2019industrie pharmaceutique pratiquant la recherche est dispos\u00e9e \u00e0 accepter ces douloureuses \u00e9conomies dans le domaine des m\u00e9dicaments dont le brevet a expir\u00e9. En revanche, elle s\u2019oppose \u00e0 la r\u00e9duction des co\u00fbts d\u00e9cid\u00e9e au d\u00e9triment des patient-e-s qui ont besoin d\u2019une prise en charge dans des cas particuliers. En effet, cette tactique risque de d\u00e9grader s\u00e9rieusement l\u2019acc\u00e8s des patient-e-s \u00e0 des m\u00e9dicaments vitaux dans des situations exceptionnelles, m\u00e9dicalement justifi\u00e9es.<\/strong><\/p>\n\n\n\n<p>Aujourd\u2019hui, le Conseil f\u00e9d\u00e9ral a adopt\u00e9 la r\u00e9vision de l\u2019Ordonnance sur l\u2019assurance-maladie (OAMal) et de l\u2019Ordonnance sur les prestations de l\u2019assurance des soins (OPAS). Durant la consultation, Interpharma et une grande majorit\u00e9 d\u2019organisations concern\u00e9es avaient fermement rejet\u00e9 le projet de r\u00e9vision. Des am\u00e9liorations ont \u00e9t\u00e9 effectu\u00e9es dans le cadre de la consultation parlementaire et de tables rondes, mais il reste des \u00e9l\u00e9ments probl\u00e9matiques et douloureux:<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-economies-de-250-millions\"><strong>\u00c9conomies de 250 millions <\/strong><strong><\/strong><\/h2>\n\n\n\n<p>Dans le syst\u00e8me de sant\u00e9, l\u2019industrie pharmaceutique est le seul acteur qui, du fait des contr\u00f4les de prix r\u00e9guliers, apporte d\u00e9j\u00e0, ann\u00e9e apr\u00e8s ann\u00e9e, des \u00e9conomies de quelque 1.2\u00a0milliard de francs. Sur le march\u00e9 des m\u00e9dicaments dont le brevet a expir\u00e9, la hausse des r\u00e9ductions de prix des g\u00e9n\u00e9riques et biosimilaires et la hausse de la quote-part diff\u00e9renci\u00e9e sont des d\u00e9cisions qui entra\u00eenent pour l\u2019industrie pharmaceutique de douloureuses \u00e9conomies suppl\u00e9mentaires de plus de 250\u00a0millions de francs. L\u2019industrie pharmaceutique est cependant dispos\u00e9e \u00e0 les accepter et \u00e0 apporter ainsi une contribution suppl\u00e9mentaire notable \u00e0 la ma\u00eetrise des co\u00fbts.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Se concentrer sur les co\u00fbts menace l\u2019acc\u00e8s des patient-e-s<\/strong><strong><\/strong><\/h2>\n\n\n\n<p>Un objectif essentiel de la r\u00e9vision de la prise en charge dans des cas particuliers (OAMal, art.&nbsp;71 a \u00e0 71d) \u00e9tait d\u2019am\u00e9liorer l\u2019\u00e9galit\u00e9 de traitement des patient-e-s. Mais par la d\u00e9cision prise aujourd\u2019hui, le Conseil f\u00e9d\u00e9ral serre essentiellement les cordons de la bourse, y compris dans le domaine ultrasensible des cas m\u00e9dicaux exceptionnels: l\u2019industrie doit \u00e0 nouveau accorder des r\u00e9ductions consid\u00e9rables sur les prix nets, de sorte qu\u2019elle ne pourra plus couvrir les co\u00fbts de certains produits. Bilan: d\u2019une part, les patient-e-s perdront l\u2019acc\u00e8s dans des cas particuliers et d\u2019autre part, les m\u00e9dicaments arriveront sur le march\u00e9 suisse avec du retard, voire plus du tout.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Le but doit \u00eatre l\u2019acc\u00e8s des patient-e-s d\u00e8s octroi de l\u2019AMM par Swissmedic<\/strong><strong><\/strong><\/h2>\n\n\n\n<p>Par sa contribution \u00e0 la ma\u00eetrise des co\u00fbts, l\u2019industrie pharmaceutique d\u00e9montre son soutien \u00e0 un financement p\u00e9renne du syst\u00e8me de sant\u00e9. En m\u00eame temps, il faut emp\u00eacher qu\u2019une tactique de r\u00e9duction des co\u00fbts menace l\u2019acc\u00e8s \u00e0 des m\u00e9dicaments innovants. Pour les entreprises pharmaceutiques pratiquant la recherche en Suisse, la r\u00e9vision de l\u2019OAMal am\u00e8ne des baisses suppl\u00e9mentaires tr\u00e8s douloureuses du chiffre d\u2019affaires. Interpharma ne peut les accepter que si le Conseil f\u00e9d\u00e9ral r\u00e9forme enfin le m\u00e9canisme obsol\u00e8te de prise en charge, de mani\u00e8re \u00e0 permettre l\u2019acc\u00e8s des patient-e-s aux m\u00e9dicaments innovants d\u00e8s le jour d\u2019octroi de l\u2019autorisation de mise sur le march\u00e9 (AMM) par Swissmedic. Pour Interpharma, il est clair qu\u2019il faut mettre au premier plan du syst\u00e8me de sant\u00e9 une prise en charge des patient-e-s rapide, de haute qualit\u00e9 et \u00e0 \u00e9galit\u00e9. Interpharma a soumis en mai 2022 une proposition en ce sens, le <a href=\"https:\/\/interpharma.ch\/fr\/blog\/medienmitteilung-interpharma-schlaegt-einen-rueckvergueteten-innovationszugang-fuer-patientinnen-und-patienten-vor\/?lang=fr\">concept de remboursement de l\u2019acc\u00e8s \u00e0 l\u2019innovation<\/a>. Celui-ci est \u00e0 pr\u00e9sent plus n\u00e9cessaire que jamais.<\/p>\n\n\n\n<p>Ren\u00e9 Buholzer, directeur d\u2019Interpharma, d\u00e9clare:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u00abPar la r\u00e9vision de l\u2019OAMal, le Conseil f\u00e9d\u00e9ral fait courir aux personnes touch\u00e9es le risque de perdre l\u2019acc\u00e8s \u00e0 des m\u00e9dicaments vitaux. Il est d\u2019autant plus urgent de moderniser les m\u00e9canismes obsol\u00e8tes de prise en charge.\u00bb<\/em><em><\/em><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Par la r\u00e9vision de l\u2019Ordonnance sur l\u2019assurance-maladie, le Conseil f\u00e9d\u00e9ral fait des \u00e9conomies suppl\u00e9mentaires de plus de 250&nbsp;millions de francs dans le domaine des m\u00e9dicaments. L\u2019industrie pharmaceutique pratiquant la recherche est dispos\u00e9e \u00e0 accepter ces douloureuses \u00e9conomies dans le domaine des m\u00e9dicaments dont le brevet a expir\u00e9. En revanche, elle s\u2019oppose \u00e0 la r\u00e9duction des [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2614,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[131,54,122],"class_list":["post-12578","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-politique","tag-medien-fr","tag-communique-de-presse"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Communiqu\u00e9 de presse : R\u00e9vision de l\u2019OAMal : la tactique de r\u00e9duction des co\u00fbts menace la prise en charge dans les cas m\u00e9dicaux exceptionnels - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Communiqu\u00e9 de presse : R\u00e9vision de l\u2019OAMal : la tactique de r\u00e9duction des co\u00fbts menace la prise en charge dans les cas m\u00e9dicaux exceptionnels\" \/>\n<meta property=\"og:description\" content=\"Par la r\u00e9vision de l\u2019Ordonnance sur l\u2019assurance-maladie, le Conseil f\u00e9d\u00e9ral fait des \u00e9conomies suppl\u00e9mentaires de plus de 250&nbsp;millions de francs dans le domaine des m\u00e9dicaments. L\u2019industrie pharmaceutique pratiquant la recherche est dispos\u00e9e \u00e0 accepter ces douloureuses \u00e9conomies dans le domaine des m\u00e9dicaments dont le brevet a expir\u00e9. En revanche, elle s\u2019oppose \u00e0 la r\u00e9duction des [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-22T12:44:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T10:18:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/01\/Revision-KVVKLV_small_FR.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"berta_admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"berta_admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/\"},\"author\":{\"name\":\"berta_admin\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\"},\"headline\":\"Communiqu\u00e9 de presse : R\u00e9vision de l\u2019OAMal : la tactique de r\u00e9duction des co\u00fbts menace la prise en charge dans les cas m\u00e9dicaux exceptionnels\",\"datePublished\":\"2023-09-22T12:44:41+00:00\",\"dateModified\":\"2026-03-03T10:18:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/\"},\"wordCount\":737,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/01\/Revision-KVVKLV_small_FR.png\",\"keywords\":[\"Politique\",\"M\u00e9dias\",\"Communiqu\u00e9 de presse\"],\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/\",\"name\":\"Communiqu\u00e9 de presse : R\u00e9vision de l\u2019OAMal : la tactique de r\u00e9duction des co\u00fbts menace la prise en charge dans les cas m\u00e9dicaux exceptionnels - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/01\/Revision-KVVKLV_small_FR.png\",\"datePublished\":\"2023-09-22T12:44:41+00:00\",\"dateModified\":\"2026-03-03T10:18:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/01\/Revision-KVVKLV_small_FR.png\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/01\/Revision-KVVKLV_small_FR.png\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Communiqu\u00e9 de presse : R\u00e9vision de l\u2019OAMal : la tactique de r\u00e9duction des co\u00fbts menace la prise en charge dans les cas m\u00e9dicaux exceptionnels\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818\",\"name\":\"berta_admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g\",\"caption\":\"berta_admin\"},\"sameAs\":[\"https:\/\/interpharma.ch\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Communiqu\u00e9 de presse : R\u00e9vision de l\u2019OAMal : la tactique de r\u00e9duction des co\u00fbts menace la prise en charge dans les cas m\u00e9dicaux exceptionnels - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/","og_locale":"fr_FR","og_type":"article","og_title":"Communiqu\u00e9 de presse : R\u00e9vision de l\u2019OAMal : la tactique de r\u00e9duction des co\u00fbts menace la prise en charge dans les cas m\u00e9dicaux exceptionnels","og_description":"Par la r\u00e9vision de l\u2019Ordonnance sur l\u2019assurance-maladie, le Conseil f\u00e9d\u00e9ral fait des \u00e9conomies suppl\u00e9mentaires de plus de 250&nbsp;millions de francs dans le domaine des m\u00e9dicaments. L\u2019industrie pharmaceutique pratiquant la recherche est dispos\u00e9e \u00e0 accepter ces douloureuses \u00e9conomies dans le domaine des m\u00e9dicaments dont le brevet a expir\u00e9. En revanche, elle s\u2019oppose \u00e0 la r\u00e9duction des [&hellip;]","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/","og_site_name":"Interpharma","article_published_time":"2023-09-22T12:44:41+00:00","article_modified_time":"2026-03-03T10:18:13+00:00","og_image":[{"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/01\/Revision-KVVKLV_small_FR.png","width":1080,"height":1080,"type":"image\/png"}],"author":"berta_admin","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"berta_admin","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/"},"author":{"name":"berta_admin","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818"},"headline":"Communiqu\u00e9 de presse : R\u00e9vision de l\u2019OAMal : la tactique de r\u00e9duction des co\u00fbts menace la prise en charge dans les cas m\u00e9dicaux exceptionnels","datePublished":"2023-09-22T12:44:41+00:00","dateModified":"2026-03-03T10:18:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/"},"wordCount":737,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/01\/Revision-KVVKLV_small_FR.png","keywords":["Politique","M\u00e9dias","Communiqu\u00e9 de presse"],"inLanguage":"fr-FR","copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/","name":"Communiqu\u00e9 de presse : R\u00e9vision de l\u2019OAMal : la tactique de r\u00e9duction des co\u00fbts menace la prise en charge dans les cas m\u00e9dicaux exceptionnels - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/01\/Revision-KVVKLV_small_FR.png","datePublished":"2023-09-22T12:44:41+00:00","dateModified":"2026-03-03T10:18:13+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/01\/Revision-KVVKLV_small_FR.png","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2023\/01\/Revision-KVVKLV_small_FR.png","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/communique-de-presse-revision-de-loamal-la-tactique-de-reduction-des-couts-menace-la-prise-en-charge-dans-les-cas-medicaux-exceptionnels\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Communiqu\u00e9 de presse : R\u00e9vision de l\u2019OAMal : la tactique de r\u00e9duction des co\u00fbts menace la prise en charge dans les cas m\u00e9dicaux exceptionnels"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/1302f3da278bb3f8995756877d107818","name":"berta_admin","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a2aeb00900e30743ff2859dfc3dd11cf7e64bb4ec7a1f349ee3772658a1d087d?s=96&d=mm&r=g","caption":"berta_admin"},"sameAs":["https:\/\/interpharma.ch"]}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=12578"}],"version-history":[{"count":2,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12578\/revisions"}],"predecessor-version":[{"id":14587,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/12578\/revisions\/14587"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/2614"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=12578"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=12578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}